Literature DB >> 17449328

Radiation-induced apoptosis along with local and systemic cytokine elaboration is associated with DC plus radiotherapy-mediated renal cell tumor regression.

Jianhua Huang1, Yao Wang, Jia Guo, Haiyan Lu, Xingshi Lin, Lin Ma, Seagal Teitz-Tennenbaum, Alfred E Chang, Qiao Li.   

Abstract

Utilizing melanoma and sarcoma tumor models syngeneic to C57BL/6 mice, we previously reported the antitumor effects of intratumoral (i.t.) administration of dendritic cells (DC) combined with localized radiotherapy (RT). However, the mechanisms underlying the augmented therapeutic effects have yet to be fully defined. Using the BALB/c host, we explored in this study the capacity of RT to augment the therapeutic efficacy of DC in the syngeneic renal cell cancer, Renca. I.t. DC administration combined with RT inhibited tumor growth in a synergistic manner. This extends our previous findings using a different host strain and two histologically distinct tumor models. More importantly, we provide evidence in this report that RT induced significant apoptosis and necrosis in Renca tumor cells, which involved down-regulated expression of Bcl-2 and a concurrent up-regulated expression of Bax. We also found significantly elevated expression of TNFalpha in RT plus DC-treated Renca tumors. Furthermore, splenocytes isolated from DC plus RT-treated mice elaborated higher levels of IL-2, IL-4, IFNgamma and IgG, IgM in response to tumor cells compared with splenocytes from monotherapy-treated hosts. These data support the conclusion that radiotherapy enhanced DC vaccination by inducing tumor cell apoptosis in BABL/c host, and the significantly augmented therapeutic efficacy by RT+DC treatment was associated with an increased local production of TNFalpha as well as an amplified systemic antitumor responses conferred by the combined therapy. I.t. DC administration in concert with localized RT may represent a promising novel regimen for human cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17449328     DOI: 10.1016/j.clim.2007.02.005

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  12 in total

Review 1.  Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination.

Authors:  Mohamed Labib Salem; David J Cole
Journal:  Cancer Immunol Immunother       Date:  2009-11-18       Impact factor: 6.968

2.  Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model.

Authors:  Seagal Teitz-Tennenbaum; Qiao Li; Mary A Davis; Alfred E Chang
Journal:  Clin Immunol       Date:  2008-10-08       Impact factor: 3.969

3.  Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer.

Authors:  Seagal Teitz-Tennenbaum; Qiao Li; Mary A Davis; Kari Wilder-Romans; Janet Hoff; Mu Li; Alfred E Chang
Journal:  J Immunother       Date:  2009 Jul-Aug       Impact factor: 4.456

4.  Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer.

Authors:  Kristen M Drescher; Poonam Sharma; Patrice Watson; Zoran Gatalica; Stephen N Thibodeau; Henry T Lynch
Journal:  Fam Cancer       Date:  2009-01-23       Impact factor: 2.375

5.  Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.

Authors:  Paula Kroon; Jules Gadiot; Marlies Peeters; Alessia Gasparini; Marcel A Deken; Hideo Yagita; Marcel Verheij; Jannie Borst; Christian U Blank; Inge Verbrugge
Journal:  Cancer Immunol Immunother       Date:  2016-05-09       Impact factor: 6.968

6.  Hypofractionated Irradiation Has Immune Stimulatory Potential and Induces a Timely Restricted Infiltration of Immune Cells in Colon Cancer Tumors.

Authors:  Benjamin Frey; Michael Rückert; Julia Weber; Xaver Mayr; Anja Derer; Michael Lotter; Christoph Bert; Franz Rödel; Rainer Fietkau; Udo S Gaipl
Journal:  Front Immunol       Date:  2017-03-08       Impact factor: 7.561

7.  Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells.

Authors:  Jiyun Yu; Rong Tian; Bingshui Xiu; Jinqi Yan; Rui Jia; Liang Zhang; Alfred E Chang; Hongbin Song; Qiao Li
Journal:  Int J Biol Sci       Date:  2009-01-20       Impact factor: 6.580

8.  Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapy.

Authors:  Kenichiro Hasumi; Yukimasa Aoki; Ryuko Watanabe; Kim G Hankey; Dean L Mann
Journal:  Cancers (Basel)       Date:  2011-04-28       Impact factor: 6.639

Review 9.  Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity.

Authors:  Aleksandra M Dudek; Shaun Martin; Abhishek D Garg; Patrizia Agostinis
Journal:  Front Immunol       Date:  2013-12-11       Impact factor: 7.561

Review 10.  Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines.

Authors:  Lien Vandenberk; Jochen Belmans; Matthias Van Woensel; Matteo Riva; Stefaan W Van Gool
Journal:  Front Immunol       Date:  2016-01-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.